

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**MTA Everolimus and sunitinib for treating unresectable or  
metastatic neuroendocrine tumours in people with  
progressive disease**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final appraisal determination**

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
Consultees commented that because of the rarity of neuroendocrine tumours, people with the disease are disadvantaged compared to more common cancers in terms of access to efficacious therapies.  It was considered that issues of access and rarity of disease are not considered equality issues under the equalities legislation. It was decided that the appraisal committee will consider whether its recommendations could have a different impact on people protected by the equality legislation.
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No equality issues were raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues were raised or discussed by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equality issues were discussed by the committee and this is noted in the summary table of the FAD.

**Approved by Associate Director (name):** Helen Knight

**Date:** 19/04/2017